Hormonal Contraceptives and Dermatology

Williams, Natalie M.; Rajabi‐Estarabadi, Ali; Keri, Jonette; Tosti, Antonella

doi:10.1007/s40257-020-00557-5

Cited by 20 publications

(25 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, this PLCA has recently seen an unexplained, almost “epidemic” increase in both prevalence and incidence [ 20 , 21 , 22 , 23 ]. To explain this, several hypotheses about environmental causes are considered plausible, including prolonged use of hormonal contraceptives [ 24 , 25 ] as well as the increased or excessive use of leave-on facial skin care/antiaging products and sunscreens [ 26 ] (particularly chemical sunscreens [ 27 ], and personal care products such as cleansers, cosmetics, creams, lotions, hair care products, etc). The association of leave-on cosmetics such as sunscreens with FFA is increasingly being proposed in the field [ 6 , 26 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

A Cell Membrane-Level Approach to Cicatricial Alopecia Management: Is Caveolin-1 a Viable Therapeutic Target in Frontal Fibrosing Alopecia?

et al. 2021

View full text Add to dashboard Cite

Irreversible destruction of the hair follicle (HF) in primary cicatricial alopecia and its most common variant, frontal fibrosing alopecia (FFA), results from apoptosis and pathological epithelial-mesenchymal transition (EMT) of epithelial HF stem cells (eHFSCs), in conjunction with the collapse of bulge immune privilege (IP) and interferon-gamma-mediated chronic inflammation. The scaffolding protein caveolin-1 (Cav1) is a key component of specialized cell membrane microdomains (caveolae) that regulates multiple signaling events, and even though Cav1 is most prominently expressed in the bulge area of human scalp HFs, it has not been investigated in any cicatricial alopecia context. Interestingly, in mice, Cav1 is involved in the regulation of (1) key HF IP guardians (TGF-β and α-MSH signaling), (2) IP collapse inducers/markers (IFNγ, substance P and MICA), and (3) EMT. Therefore, we hypothesize that Cav1 may be an unrecognized, important player in the pathobiology of cicatricial alopecias, and particularly, in FFA, which is currently considered as the most common type of primary lymphocytic scarring alopecia in the world. We envision that localized therapeutic inhibition of Cav1 in management of FFA (by cholesterol depleting agents, i.e., cyclodextrins/statins), could inhibit and potentially reverse bulge IP collapse and pathological EMT. Moreover, manipulation of HF Cav1 expression/localization would not only be relevant for management of cicatricial alopecia, but FFA could also serve as a model disease for elucidating the role of Cav1 in other stem cell- and/or IP collapse-related pathologies.

show abstract

Section: Introductionmentioning

confidence: 99%

A Cell Membrane-Level Approach to Cicatricial Alopecia Management: Is Caveolin-1 a Viable Therapeutic Target in Frontal Fibrosing Alopecia?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Evidence suggests that progesterone-only contraceptives, such as the etonogestrel implant, can trigger or worsen many skin conditions, including acne, hirsutism, rosacea, and alopecia. 2 However, the relationship between progestin and TEN has not been investigated. One case report discusses TEN secondary to levonorgestrel- and ethinyl estradiol–containing contraceptive pill use.…”

Section: Discussionmentioning

confidence: 99%

Toxic epidermal necrolysis caused by etonogestrel implantation: A rare presentation

Amin

Liao

2022

JAAD Case Reports

View full text Add to dashboard Cite

“…There is limited and anecdotal evidence suggesting that combined oral contraceptives (COCs) may worsen HS severity, particularly those with a higher progesterone-to-estrogen ratio. Alternatively, COCs with increased estrogen-to-progesterone ratios have been shown to improve HS symptoms and flares [ 8 ]. Worsening of HS has also been noted in women using medroxyprogesterone acetate and hormonal intrauterine devices, both of which are progesterone based [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Section: Descriptionmentioning

confidence: 99%

Five-Year Remission of Hidradenitis Suppurativa Following the Removal of a Levonorgestrel Intrauterine Device and Disease Overview for Obstetrics and Gynecology Providers

Hengy

Cevigney

Tur

et al. 2022

Cureus

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that is characterized by recurrent, painful nodules, sinus tract formation, and scarring. We report the case of a 20-year-old female with the abrupt onset of Hurley stage I HS following the implantation of a levonorgestrel intrauterine device (IUD) and complete remission of disease following the removal of the device one year later. To our knowledge, this is the first documented case of long-term remission of HS after the removal of levonorgestrel IUD. We also provide a concise overview of HS and suggested primary interventions for obstetrics and gynecology providers.

show abstract

Hormonal Contraceptives and Dermatology

Cited by 20 publications

References 107 publications

A Cell Membrane-Level Approach to Cicatricial Alopecia Management: Is Caveolin-1 a Viable Therapeutic Target in Frontal Fibrosing Alopecia?

A Cell Membrane-Level Approach to Cicatricial Alopecia Management: Is Caveolin-1 a Viable Therapeutic Target in Frontal Fibrosing Alopecia?

Toxic epidermal necrolysis caused by etonogestrel implantation: A rare presentation

Five-Year Remission of Hidradenitis Suppurativa Following the Removal of a Levonorgestrel Intrauterine Device and Disease Overview for Obstetrics and Gynecology Providers

Contact Info

Product

Resources

About